Roche Can Extend Lymphoma Lead But Is Still Playing Catch-Up In Myeloma And CAR-T
Fierce Competition In Bispecifics And Allo CAR-Ts
Executive Summary
Roche looks set to keep the upper hand in lymphoma with Polivy and its twin bispecific drugs, but Johnson & Johnson remains the company to beat in multiple myeloma.